<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">DE FELICE, FRANCESCA</style></author><author><style face="normal" font="default" size="100%">FALLARINO, ALESSIA</style></author><author><style face="normal" font="default" size="100%">IAFRATE, FRANCO</style></author><author><style face="normal" font="default" size="100%">MAIURI, VERONICA</style></author><author><style face="normal" font="default" size="100%">GALLONI, GIOVANNI</style></author><author><style face="normal" font="default" size="100%">COLONNA, GIOVANNI TURRIZIANI</style></author><author><style face="normal" font="default" size="100%">DE PIETRO, RAFFAELLA</style></author><author><style face="normal" font="default" size="100%">CHIARELLO, GIUSEPPINA</style></author><author><style face="normal" font="default" size="100%">MARCHETTI, CLAUDIA</style></author><author><style face="normal" font="default" size="100%">BULZONETTI, NADIA</style></author><author><style face="normal" font="default" size="100%">MUSIO, DANIELA</style></author><author><style face="normal" font="default" size="100%">TOMBOLINI, VINCENZO</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">The INCH Trial – Induction Chemotherapy in Patients With Bulky Anal Canal Cancer: Evaluation of the Pilot Phase</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021-06-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">3187-3191</style></pages><doi><style  face="normal" font="default" size="100%">10.21873/anticanres.15105</style></doi><volume><style face="normal" font="default" size="100%">41</style></volume><issue><style face="normal" font="default" size="100%">6</style></issue><abstract><style  face="normal" font="default" size="100%">Aim: To assess feasibility, complications and efficacy of induction chemotherapy followed by standard chemoradiotherapy in patients with bulky anal canal cancer. Patients and Methods: Patients with squamous cell carcinoma of the anal canal, staged bulky tumor with or without nodal involvement were prospectively enrolled. Before standard chemoradiotherapy, patients received induction chemotherapy with 3 cycles of 75 mg/m2 cisplatin and 750 mg/m2 5-fluorouracil. Patients were followed-up routinely until recurrence or death. Results: Seven patients with bulky anal canal cancer were evaluable for this pilot phase of the study. All patients had human papillomavirus-negative disease. Five completed the scheduled induction chemotherapy and all patients completed the programmed concomitant chemoradiotherapy. None had severe hematological toxicity. The majority of patients (6/7) had tumor downsizing after induction treatment. Six months after chemoradiotherapy, complete response was documented in three patients and salvage surgery was performed in two cases. With a median follow-up of 38 months (range=28-48 months), two patients are disease-free survivors. Conclusion: Induction chemotherapy has the potential to become a standard approach in patients with bulky human papillomavirus-negative anal canal cancer.</style></abstract></record></records></xml>